Member Info for GloriaMarket

Mr James, I've read the RNS but the only positives in the RNS are those that were previously published.

However, this RNS introduced several new negatives. Cashburn up from 430k (in june, I think) to 500k, tax relief down from 800k to 700k due to lack of government funds available and see Mr Rogers post for expected timings .

Perhaps you simply aren't up to speed on previous GDR RNS's, which would account your opinion that there are new positive aspects in the RNS. Understandable.

Mr James,

What were the positives in this RNS that shareholders were not already aware of?

How can a shorter get it wrong if the price is down on opening? Anyone with a short position will have increased their paper profit. Mr Carrots, you are a silly boy.

"Holding steady so far. 6% is nothing in the grand scheme of things,"

I think you mean that the market had expected this RNS and as such the SP has barely moved?

1.5p by christmas?

"In closing, I would like to extend my sincere gratitude to you, our valued shareholders especially for the considerable financial support shown at the time of our financing, along with our dedicated staff and collaboration partners, for your continued effort.

Dr Ian Gilham

Chairman"

I feel Dr Gilham should've added "Merry Christmas!" to the end of his statement.

"The Group's operating expenses are currently running at

around £0.5m per month and are expected to be maintained at around this level pending

increased commercial traction."

cash burn now 500k per month.

"Revenue and other income £0.5m (2023: £0.06m)" revenue this year is almost 10x more than last year. SP should be 10p by noon.

CFO probably has to state this to avoid shareholders suing the company when it does go bust. Sorry , IF it does go bust.

The Company recognises the uncertainty regarding the timing of the associated revenue

generation, given we are at the forefront of the emerging pharmacogenetic field and the

funding complexities within the NHS are understood. National Commissioning of our

products brings significant upside to the sales forecasts, but it is outside of our control

and therefore the timing is difficult to predict.

The various forecast scenarios that were considered by the Board, identify costs

mitigations that could extend the cash runway, and the Directors have reasonable

confidence in their ability to raise additional financing if required to bridge the funding

gap to a positive EBITDA position. While the Board has a successful track record in

raising funds, there remains uncertainty as to the amount of funding that could be raised

from shareholders or debt providers.

CFO states... As described in the accounting policies, we continue to adopt a going concern basis for

the preparation of the accounts, but the combination of the above factors represent a

material uncertainty that may cast significant doubt on the Group and Company's ability

to continue as a going concern.

Financial Highlights

· Revenue and other income £0.5m (2023: £0.06m)

· Operating loss for the year of £5.3m (2023: loss of £5.2m)

· R&D spend of £4.2m (2023: £3.9m) focused on near-commercialisation product

development

· Successful equity fundraise of £6m (gross) announced in June 2024

· Cash at bank of £5.2m at 30 June 2024 (2023: £2.6m) and debt free

Results @7am? it's like waiting for Christmas morning. 3 minutes to go..

Genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces it will release its preliminary results for the year ended 30 June 2024 on Friday, 29 November 2024.

The Company will provide a live presentation to accompany the results, presented by CEO, Gino Miele and CFO, Russ Shaw on Monday, 2 December 2024 at 2pm GMT.

"Pretty much saved the company and we’re still none the wiser as to why he left so abruptly."

Under Mr Cheeks watch the company was saved. How big was the role Mr Cheek pplayed in preventing sprialling further to its death ? We will never know, but if he was instrumental in saving the company and was pushed to leave only months later, then it suggests that GDR has a major senior management problem. But tbh I think we all agree that GDR has always had major senior management problems, and in that regard Mr Cheeks departure has changed absolutely nothing.

"I Think a few on here will be suprized tomorrow at the big steps forward the company have made over the last 6 months..imho"

The only posters who could possibly be surprised are those who are pessimistic about tomorrow.

11 babies and 4000 tests. This is priceless, imo. I pity the poor babies at other trusts and countries who have lost their hearing, unnecessarily.

"Russ on the other hand has appeared rather taciturn and reluctant to say one word more than he has to. As long as he can speak confidently about the numbers and give good projections that’ll do for me."

Do you think Mr Shaw will give investors a warning , like he did last year when he told us that GDR would not survive as an on-going concern after 24Q1 without funding? STrangely a week or so after announcing funding issues, RF opened the money pit and provided enough funding to last until PH and PI's stepped up to the plate in May 2024.

"I am honestly surprised this hasn't been at over 3p since pretty much the day after the director buy RNS in August. I was hoping it would have hit over 3p."

is there a website where GDR investors copy and paste their daily messages from?

" The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester. "

whoever came up with that sentence obviously thought it deserved to be repeated twice in the RNS.